Overview

An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II

Status:
Not yet recruiting

Trial end date:
2023-12-31

Target enrollment:

Participant gender:

Summary

The primary objective of this extension study is to assess the long-term safety and efficacy of AVTX-803 in subjects with LAD II (SLC35C1-CDG).

Phase:

Phase 3

Details

Lead Sponsor:

Avalo Therapeutics, Inc.